ESMO 2023: Focus on Bladder Cancer
Stay up-to-date with the latest research and clinical updates on bladder cancer from the ESMO 2023 Congress.
Dr. Nizam provides an overview of her recent research on biomarkers of TRAEs associated with EV for aUC.
Dr. Evan Yu opines on whether the EV-302 and CheckMate 901 data are practice-changing and when to recommend each combo.
Enfortumab vedotin shows promising activity and tolerability in cisplatin-ineligible patients with MIBC.
Erdafitinib was found to significantly improve OS and boost benefit over chemotherapy in patients with FGFRalt advanced/mUC.
Results of the phase 2b SunRISe-1 trial showed TAR-200 yields complete responses in BCG-unresponsive high-risk NMIBC.
Drs. McGregor, Sonpavde highlight the Double Antibody Drug conjugate trial, updates from THOR, and other studies.
Drs. McGregor, Sonpavde share how the data compare across CheckMate 901 and EV-302, as well as considerations for physicians.
Paclitaxel administered with tremelimumab provided encouraging antitumor activity with a manageable safety profile.
The TAR-210 delivery system provides a continuous release of erdafitinib to the bladder while limiting systemic toxicities.
The practice-changing results were presented at ESMO 2023.
Nivolumab plus gemcitabine-cisplatin demonstrated meaningful improvements in OS and PFS as first-line treatment of mUC.
An LBA shed light on the effects of erdafitinib in patients with high-risk NMIBC with select FGFR alterations after BCG.
The combination of sacituzumab govitecan plus enfortumab vedotin was found to be safe, and provides a high ORR.
PET patients were more likely to have a change in treatment compared with receiving CT alone.
Erdafitinib and pembrolizumab had similar OS rates, and toxicities were manageable with dose modifications.
Advertisement
Advertisement
